Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial

This publication has 27 references indexed in Scilit:

• Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
  New England Journal of Medicine, 1999
• Thalidomide in Crohn's disease
  The Lancet, 1997
• Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-α) inhibition suggest drugs capable of selective gene regulation
  Clinical and Experimental Immunology, 1997
• Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients
  Rheumatology, 1997
• Thalidomide Inhibits Tumor Necrosis Factor- Production by Lipopolysaccharide- and Lipoarabinomannan-Stimulated Human Microglial Cells
  The Journal of Infectious Diseases, 1995
• The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures
  Clinical and Experimental Immunology, 1995
• Detection of tumour necrosis factor alpha in sarcoidosis and tuberculosis granulomas using in situ hybridisation.
  Journal of Clinical Pathology, 1994
• Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease.
  Gut, 1993
• Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine
  Clinical and Experimental Immunology, 1990
• Treatment of Crohn's Disease with 6-Mercaptopurine
  New England Journal of Medicine, 1980